A virtual clinical trial of psychedelics to treat patients with disorders of consciousness
Naji L.N. Alnagger,Paolo Cardone,Charlotte Martial,Yonatan Sanz Perl,Ivan Mindlin,Jacobo D Sitt,Leor Roseman,Robin Carhart-Harris,David Nutt,Pablo Mallaroni,Natasha L Mason,Johannes G Ramaekers,Vincent Bonhomme,Steven Laureys,Gustavo Deco,Olivia Gosseries,Pablo Nunez,Jitka Annen
DOI: https://doi.org/10.1101/2024.08.16.608251
2024-08-19
Abstract:Disorders of consciousness (DoC), including the unresponsive wakefulness syndrome (UWS) and the minimally conscious state (MCS), have limited treatment options. Recent research suggests that psychedelic drugs, known for their complexity-enhancing properties, could be promising treatments for DoC. This study uses whole-brain computational models to explore this potential. We created individualised models for DoC patients, optimised with empirical fMRI and diffusion-weighted imaging (DWI) data, and simulated the administration of LSD and psilocybin. We used an in-silico perturbation protocol to distinguish between different states of consciousness, including DoC, anaesthesia, and the psychedelic state, and assess the dynamical stability of the brains of DoC patients pre- and post-psychedelic simulation. Our findings indicate that LSD and psilocybin shift DoC patients' brains closer to criticality, with a greater effect in MCS patients. In UWS patients, the treatment response correlates with structural connectivity, while in MCS patients, it aligns with baseline functional connectivity. This virtual clinical trial lays a computational foundation for using psychedelics in DoC treatment and highlights the future role of computational modelling in drug discovery and personalised medicine.
Neuroscience